Viatris Inc. (VTRS)
9.15
-0.29 (-3.07%)
At close: Mar 21, 2025, 3:59 PM
-3.07% (1D)
| Bid | 9.23 |
| Market Cap | 10.92B |
| Revenue (ttm) | 14.73B |
| Net Income (ttm) | -634.25M |
| EPS (ttm) | -0.53 |
| PE Ratio (ttm) | -17.26 |
| Forward PE | 4.24 |
| Analyst | Hold |
| Ask | 9.33 |
| Volume | 17,410,305 |
| Avg. Volume (20D) | 11,787,636.6 |
| Open | 9.36 |
| Previous Close | 9.44 |
| Day's Range | 9.02 - 9.37 |
| 52-Week Range | 8.77 - 13.55 |
| Beta | 0.92 |
About VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, end...
Sector Healthcare
IPO Date Mar 17, 1980
Employees 32,000
Stock Exchange NASDAQ
Ticker Symbol VTRS
Website https://www.viatris.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VTRS stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 9.29% from the latest price.
Stock ForecastsNext Earnings Release
Viatris Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-15.21%
Viatris shares are trading lower after the company...
Unlock content with
Pro Subscription
3 weeks ago
-15.21%
Viatris shares are trading lower after the company reported Q4 EPS and sales below estimates.
